-
A Breakthrough in Hepatitis B: AusperBio Reports Sustained Functional Cure
A New Milestone in Chronic Hepatitis B Research In a significant development for global health, AusperBio has announced encouraging results from its clinical studies regarding chronic hepatitis B (CHB). The company reported that patients have maintained a sustained functional cure for up to 15 months after stopping all antiviral treatment. Understanding the Clinical Results The…
-
New Hope for Chronic Hepatitis B: Understanding the FDA Approval of Hepcludex (bepirovirsen)
NYSE: $GSK A Significant Milestone in Liver Health The landscape of chronic hepatitis B (CHB) treatment is evolving. Recently, the FDA reached a significant decision regarding Hepcludex (bepirovirsen), providing new options for patients managing this complex viral infection. This development marks a noteworthy step forward in therapeutic approaches for those living with chronic liver disease.…
-
Progress Report: Aligos Therapeutics’ SUPREME Trial in Hepatitis B
NASDAQ: $ALGS Aligos Therapeutics recently issued an update concerning the progress of its Phase 2b SUPREME study, a significant development in the ongoing effort to find effective treatments for chronic Hepatitis B virus (HBV) infection. For those following pharmaceutical advancements in virology, this announcement provides valuable insight into the trajectory of their lead candidate. The…